Document Detail

Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.
MedLine Citation:
PMID:  23292869     Owner:  NLM     Status:  In-Data-Review    
MicroRNA-34 family has anti-proliferative and apoptotic roles. Recent studies have shown that p53 upregulates miR-34 family leading to direct repression of several key oncogenes. Inactivation of miR-34a has been reported in multiple types of malignancies including breast cancer. The critical role of miR-34a in p53-mediated cell cycle arrest and apoptosis invokes studies focusing on the specific role of miR-34a dysregulation in carcinogenesis. While presence of p53 mutations has frequently been described in breast cancer, still most of the breast tumors do not show any variation in the p53 coding sequence or protein expression. Therefore, it is important to clarify possible involvement of other mediators of p53 pathway in breast cancer. In this study, expression of mature miR-34a in breast tumors with wild-type p53 was investigated in order to find any correlation between dysregulation of miR-34a expression and breast cancer. In about 40 % of the wild-type p53 samples, miR-34a was significantly downregulated. Neither hypermethylation of the miR-34a promoter nor genetic variations of the p53-binding site were detected in tumor samples with downregulated miR-34a. This study has provided evidence that miR-34a expression can be affected in a significant proportion of breast tumors independent of p53. Furthermore, downregulation of miR-34a was significantly associated with metastasis, while there was a significant correlation between upregulation of miR-34a and non-metastatic condition indicating a protective role for miR-34a against more invasive disease. Knowledge of miR-34a status may provide additional useful information regarding the nature of breast tumors, especially when p53 testing does not show any aberration.
Arash Javeri; Massoud Ghaffarpour; Masoumeh Fakhr Taha; Massoud Houshmand
Related Documents :
24487789 - Molecular tests as prognostic factors in breast cancer.
25114849 - Molecular pathogenesis of bone metastases in breast cancer: proven and emerging therape...
23161709 - Molecular pathology of breast cancer: what a pathologist needs to know.
24207129 - Towards automated on-line adaptation of 2-step imrt plans: quasimodo phantom and prosta...
1160459 - Laser excision of carcinoma of the larynx.
23194119 - In situ and intraductal epithelial proliferations of prostate: definitions and treatmen...
8634959 - Legal and ethical issues in genetic testing and counseling for susceptibility to breast...
21694469 - Correlation of d dimer and factor viii levels with histopathology in patients with brea...
8411259 - Elevation of multiple serum markers in patients with stage i ovarian cancer.
Publication Detail:
Type:  Journal Article     Date:  2013-01-06
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  413     Citation Subset:  IM    
Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), P.O. Box: 161-14965, Tehran, Iran,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A PML/RARA chimeric gene on chromosome 12 in a patient with acute promyelocytic leukemia (M4) associ...
Next Document:  Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung...